Investor Relations
Financial calendar
Half-year report
21/08/25Q3 report
13/11/25Full-year report
05/02/26Annual Report for 2025
05/05/26
Latest press releases
Bulletin from the Annual General Meeting of Expres2ion Biotech Holding AB held on 28 May 2025
The Annual General Meeting 2025 (the "AGM") of ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") was held today on 28 May 2025. Notice of the AGM and complete proposals for resolutions taken are available on the Company's investor website, https://investor.expres2ionbio.com.
Read moreExpreS2ion Biotech Announces Analysguiden Publishes Equity Research Report
Hørsholm, Denmark, 23 May 2025 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion" or the “Company”) is pleased to announce that Analysguiden has published a new analyst report with a revised price target of SEK 75 (previously SEK 91).
Read moreExpreS2ion Biotech Announces Pareto Securities Analyst Update on Q1 2025 Results and Clinical Trial Progress
Hørsholm, Denmark, 21 May 2025 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion" or the “Company”) is pleased to announce that that Pareto Securities has published a new analyst newsflash following the Company’s recently reported Q1 2025 financial results and clinical trial developments.
Read moreLatest presentations
Presentation of 2025
first quarter results
15 May 2025
2024 Q4 and Full-Year
Report Webcast
6 February 2025
Stora Aktiedagarna
Stockholm
27 November 2024